Dactavira Plus — Competitive Intelligence Brief

Dactavira Plus (Dactavira Plus) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct-acting antiviral (DAA) combination. Area: Virology / Hepatology.

phase 3 Direct-acting antiviral (DAA) combination Virology / Hepatology Small molecule

Target snapshot

Dactavira Plus (Dactavira Plus) — Egyptian Liver Hospital. Dactavira Plus is a direct-acting antiviral combination therapy designed to inhibit hepatitis C virus replication through multiple viral targets.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dactavira Plus TARGET	Dactavira Plus	Egyptian Liver Hospital	phase 3	Direct-acting antiviral (DAA) combination
Zepatier plus Sofosbuvir	Zepatier plus Sofosbuvir	Massachusetts General Hospital	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A, NS3/4A protease, NS5B RNA polymerase
sofosbubir/velpatasvir/voxilaprevir	sofosbubir/velpatasvir/voxilaprevir	Partners in Health	marketed	Direct-acting antiviral (DAA) combination	HCV NS5B polymerase, NS5A protein, NS3/4A protease
Sofosbuvir and Velpatasvir	Sofosbuvir and Velpatasvir	Hannover Medical School	marketed	Direct-acting antiviral (DAA) combination	HCV NS5B polymerase and NS5A protein
Viekira Pak ± ribavirin	Viekira Pak ± ribavirin	Massachusetts General Hospital	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A protein, HCV NS3/4A serine protease
Elbasvir / Grazoprevir Oral Tablet [Zepatier]	Elbasvir / Grazoprevir Oral Tablet [Zepatier]	University of Maryland, Baltimore	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A protein and HCV NS3/4A serine protease
sofosbubir/velpatasvir	sofosbubir/velpatasvir	Partners in Health	marketed	Direct-acting antiviral (DAA) combination	HCV NS5B polymerase and NS5A protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Direct-acting antiviral (DAA) combination class)

1. Massachusetts General Hospital · 3 drugs in this class
2. Egyptian Liver Hospital · 3 drugs in this class
3. Hannover Medical School · 2 drugs in this class
4. University of Maryland, Baltimore · 2 drugs in this class
5. Iran Hepatitis Network · 2 drugs in this class
6. Partners in Health · 2 drugs in this class
7. HaEmek Medical Center, Israel · 1 drug in this class
8. Almaza Military Fever Hospital · 1 drug in this class
9. Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba · 1 drug in this class
10. Federal University of São Paulo · 1 drug in this class